As mutated genes such as KRAS and P53 are commonly observed in pancreatic cancer, gene silencing strategy induced by oligonucleotide drugs could be the promising therapy for the treatment of pancreatic cancer but remain challenging owing to the delivery obstacles (Hu et al., 2020). The gene discussed is TP53; the disease is familial pancreatic carcinoma.